Ecopetrol S.A. American Depositary Shares (EC)
Live price chart, market sentiment, and community perspectives for Ecopetrol S.A. American Depositary Shares (NYSE: EC).
Live price chart, market sentiment, and community perspectives for Ecopetrol S.A. American Depositary Shares (NYSE: EC).
On our desk, Ecopetrol presents a classic emerging-market valuation paradox. Sure, the Q2 2026 numbers look phenomenal—revenue up 35% and net income soaring 235% YoY on strong Brent averages near $97/bl—but you cannot ignore the governance layer. With the Colombian government holding an ~88% stake and an anti-oil executive branch calling the shots, institutional money remains skittish. Even with a cheap trailing P/E of around 11.44 and a juicy 3.67% dividend yield, the political risk premium demands caution. We are keeping our sizing disciplined until we see how upcoming local asset blockades and regulatory shifts pan out.
Looking at the fundamental metrics from a quantitative perspective, EC screens surprisingly well on a Quality-at-Value (QAV) framework, boasting a low price-to-operating cash flow around 2.74 and strong gross margins near 37.1%. However, short interest has dropped down to 6.6 million shares (0.3% of the float), indicating that direct bearish positioning has largely washed out, leaving the stock vulnerable to broader crude oil price swings. With production sitting around 706,000 boepd despite environmental and electrical disruptions, execution risk on their 2026 guidance remains the primary variable for short-term price discovery.
When evaluating the operational pipeline for EC, my focus as a senior analyst zeroes in on their inorganic growth and infrastructure expansion, specifically the Brava Energia acquisition process and the ISA transmission contracts totaling $428 million. Management is aggressively attempting to diversify away from pure-play upstream crude into natural gas and energy transition infrastructure, supplying roughly 62% of Colombia's natural gas demand. Analysts remain split—UBS maintains a hold rating with a $16 target while consensus averages around $13.65—so traders need to weigh near-term refining cash flows against long-term capital allocation efficacy.
Explore plasma cleansing, somatic organ swaps, and BCI.